Opinion
Video
Author(s):
"The approach is often to identify what treatments the patients have tried already, so we don't try those again, and then have a discussion about the pros and cons," says J. Quentin Clemens, MD, MSCI.
In this video, J. Quentin Clemens, MD, MSCI, provides a summary of a talk he gave at the 2025 Desai Sethi Urology Institute Urology on the Beach meeting titled “Tailoring IC Therapies for the Individual Patient.” Clemens is the Edward J McGuire Professor of Urology, program director for the Urogynecology and Reconstructive Pelvic Surgery Fellowship, Urology, and associate chair for Research, Urology, at the University of Michigan, Ann Arbor.
I started by saying, unfortunately, there aren't many examples where we can do that. In other words, the approach is often to identify what treatments the patients have tried already, so we don't try those again, and then have a discussion about the pros and cons. However, there are a few examples. The first is patients with Hunner lesions, where it's very important to identify them, because that's a totally different treatment approach, where you target the lesions and can augment that with oral cyclosporine. So that's important. The second is, many patients will have pelvic muscle tenderness, and that's a feature of really, most pelvic pain conditions. But the point is that if they have that, and that contributes to their symptoms, so if they have tenderness, and they say, "yes, when you push there, it hurts, and that's part of the symptoms I have," those patients will benefit from pelvic floor physical therapy, and so they should be referred for that. And so those are 2 clear areas.
This transcription was AI generated and edited by human editors for clarity.
FDA approves oral sulopenem for uncomplicated urinary tract infection